BAY 1211163 / Bayer - LARVOL DELTA

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Bayer | Trial completion date: Apr 2024 ➔ Sep 2023 | Active, not recruiting ➔ Terminated; Company Decision.

Trial completion date • Trial termination • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Bayer | Trial primary completion date: Mar 2024 ➔ Aug 2023

Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting | N=36 ➔ 16

Enrollment change • Enrollment closed • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bayer | Trial completion date: Oct 2023 ➔ Apr 2024 | Trial primary completion date: Sep 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2023 ➔ Oct 2023 | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bayer | Trial completion date: Mar 2023 ➔ Jul 2023 | Trial primary completion date: Feb 2023 ➔ Jun 2023

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Bayer | Trial completion date: Sep 2022 ➔ Mar 2023 | Trial primary completion date: Aug 2022 ➔ Feb 2023

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Bayer; Trial completion date: May 2022 ➔ Sep 2022; Trial primary completion date: Apr 2022 ➔ Aug 2022

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Bayer; Trial completion date: Feb 2022 ➔ May 2022; Trial primary completion date: Dec 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Respiratory Distress Syndrome • Respiratory Diseases

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Bayer

Clinical • New P1 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases